Novo Nordisk A/S (NVO) Tax Rate: 21.53%
Is Novo Nordisk A/S’s tax rate high or low?
Novo Nordisk A/S's tax rate of 21.53% is in line with its 5-year average of 20.27%, near the high end of its 5-year range (19.17%–21.53%).
2.21% above its 12-month average of 21.07%.
NVO Tax Rate Chart
NVO Average Tax Rate Chart
NVO Current vs Average Tax Rate Chart
NVO Tax Rate Metrics
TAX RATE
21.53%
TAX RATE AVG TTM
21.07%
TAX RATE AVG 3Y
20.45%
TAX RATE AVG 5Y
20.27%
TAX RATE AVG 10Y
20.22%
TAX RATE AVG 15Y
20.85%
TAX RATE AVG 20Y
21.21%
CURRENT VS TTM AVG
+2.21%
CURRENT VS 3Y AVG
+5.31%
CURRENT VS 5Y AVG
+6.20%
CURRENT VS 10Y AVG
+6.46%
CURRENT VS 15Y AVG
+3.27%
CURRENT VS 20Y AVG
+1.51%
Novo Nordisk A/S Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Tax Rate FAQ
- What is the tax rate for Novo Nordisk A/S (NVO)?
- The tax rate for NVO stock is 21.53%.
- Is Novo Nordisk A/S's tax rate high or low?
- Novo Nordisk A/S's tax rate of 21.53% is in line with its 5-year average of 20.27%, near the high end of its 5-year range (19.17%–21.53%).
- What is the TTM average tax rate for Novo Nordisk A/S (NVO)?
- The TTM average tax rate for NVO stock is 21.07%.
- What is the 3Y average tax rate for Novo Nordisk A/S (NVO)?
- The 3Y average tax rate for NVO stock is 20.45%.
- What is the 5Y average tax rate for Novo Nordisk A/S (NVO)?
- The 5Y average tax rate for NVO stock is 20.27%.
- What is the 10Y average tax rate for Novo Nordisk A/S (NVO)?
- The 10Y average tax rate for NVO stock is 20.22%.
- What is the 15Y average tax rate for Novo Nordisk A/S (NVO)?
- The 15Y average tax rate for NVO stock is 20.85%.
- What is the 20Y average tax rate for Novo Nordisk A/S (NVO)?
- The 20Y average tax rate for NVO stock is 21.21%.
Novo Nordisk A/S Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 21.53% |
| 2024-12-31 | 20.60% |
| 2023-12-31 | 20.05% |
| 2022-12-31 | 19.60% |
| 2021-12-31 | 19.17% |
| 2020-12-31 | 20.69% |
| 2019-12-31 | 19.78% |
| 2018-12-31 | 18.87% |
| 2017-12-31 | 21.67% |
| 2016-12-31 | 20.66% |
| 2015-12-31 | 19.83% |
| 2014-12-31 | 22.33% |
| 2013-12-31 | 22.60% |
| 2012-12-31 | 22.94% |
| 2011-12-31 | 22.02% |
| 2010-12-31 | 21.23% |
| 2009-12-31 | 23.02% |
| 2008-12-31 | 24.04% |
| 2007-12-31 | 22.35% |
| 2006-12-31 | 29.59% |
| 2005-12-31 | 28.76% |
| 2004-12-31 | 32.75% |
| 2003-12-31 | 33.39% |
| 2002-12-31 | 34.98% |
| 2001-12-31 | 35.97% |
| 2000-12-31 | 36.26% |
| 1999-12-31 | 40.31% |
| 1998-12-31 | 36.47% |
| 1997-12-31 | 30.03% |
| 1996-12-31 | 28.73% |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar